U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365592) titled 'Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC' on Dec. 08, 2025.
Brief Summary: This is an open-label, multicenter, phase Ib/II combined trial of sitagliptin, XELOX chemotherapy regimen, and PD-1 monoclonal antibody in the treatment of proficient mismatch repair locally advanced colorectal cancer.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer
Intervention:
DRUG: Oxaliplatin
Oxaliplatin 130mg/m2 for inducing chemotherapy in Day 1 every 3 weeks and repeat for two cycles.
DRUG: Capecitabine
Oral Capecitabine 1000 mg/m2 twice daily combined with ox...